Loading...
XWARMAB
Market cap33mUSD
Dec 23, Last price  
8.46PLN
1D
-1.17%
1Q
-48.60%
Jan 2017
-88.60%
IPO
-37.10%
Name

Mabion SA

Chart & Performance

D1W1MN
XWAR:MAB chart
P/E
3.31
P/S
0.90
EPS
2.55
Div Yield, %
0.00%
Shrs. gr., 5y
4.31%
Rev. gr., 5y
%
Revenues
152m
-7.50%
01,527,582985,375884,7845,800829,7002,733,0000000056,873,000163,982,000151,678,000
Net income
41m
+77.94%
0471,44900-3,891,200-4,461,200-4,597,000-55,826,000-57,887,000-68,870,000-64,708,000-57,188,0001,903,00023,192,00041,269,000
CFO
-2m
L
0000-27,589,100-24,386,500-33,969,000-15,221,000-54,127,000-38,938,000-33,755,000-35,239,000-32,910,00038,839,000-2,333,000
Earnings
Apr 14, 2025

Profile

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
URL
https://www.mabion.eu/
IPO date
Aug 10, 2010
Employees
248
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
151,678
-7.50%
163,982
188.33%
56,873
 
Cost of revenue
83,516
141,773
45,583
Unusual Expense (Income)
NOPBT
68,162
22,209
11,290
NOPBT Margin
44.94%
13.54%
19.85%
Operating Taxes
8,625
(1,152)
(12,158)
Tax Rate
12.65%
NOPAT
59,537
23,361
23,448
Net income
41,269
77.94%
23,192
1,118.71%
1,903
-103.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
117,480
BB yield
-12.36%
Debt
Debt current
32,880
3,087
18,170
Long-term debt
7,248
10,960
7,106
Deferred revenue
31,802
31,172
32,159
Other long-term liabilities
405
(377)
434
Net debt
(7,689)
(39,811)
(23,637)
Cash flow
Cash from operating activities
(2,333)
38,839
(32,910)
CAPEX
(37,997)
(16,731)
(31,615)
Cash from investing activities
(37,982)
(16,064)
(31,283)
Cash from financing activities
34,494
(17,844)
110,505
FCF
16,709
22,313
(59,977)
Balance
Cash
47,817
53,638
48,707
Long term investments
220
206
Excess cash
40,233
45,659
46,069
Stockholders' equity
(119,667)
(160,936)
(184,130)
Invested Capital
305,478
275,518
290,400
ROIC
20.49%
8.26%
9.73%
ROCE
36.68%
19.32%
10.62%
EV
Common stock shares outstanding
16,162
16,162
15,555
Price
18.15
-13.57%
21.00
-65.63%
61.10
194.46%
Market cap
293,346
-13.57%
339,401
-64.29%
950,428
233.80%
EV
285,657
299,590
926,791
EBITDA
75,361
31,186
20,136
EV/EBITDA
3.79
9.61
46.03
Interest
1,038
1,698
1,286
Interest/NOPBT
1.52%
7.65%
11.39%